Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–60. https://doi.org/10.1093/eurheartj/ehx419.
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the american college of cardiology/American Heart Association task force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC guideline for the management of patients with Non-ST-elevation acute coronary Syndromes, and 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123-155. https://doi.org/10.1161/cir.0000000000000404.
Wang D, Yang XH, Zhang JD, et al. Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis. BMC Cardiovasc Disord. 2018;18(1):217. https://doi.org/10.1186/s12872-018-0948-4.
Article CAS PubMed PubMed Central Google Scholar
Claassens DMF, Bergmeijer TO, Vos GJA, et al. Clopidogrel versus ticagrelor or prasugrel after primary percutaneous coronary intervention according to CYP2C19 genotype: a popular genetics subanalysis. Circ Cardiovasc Interv. 2021;14(4):e009434. https://doi.org/10.1161/circinterventions.120.009434.
Article CAS PubMed Google Scholar
Fan W, Plent S, Prats J, et al. Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice. Am J Cardiol. 2016;117(9):1439–43. https://doi.org/10.1016/j.amjcard.2016.02.012.
Article CAS PubMed Google Scholar
Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50(19):1822–34. https://doi.org/10.1016/j.jacc.2007.07.051.
Article CAS PubMed Google Scholar
Capodanno D, Angiolillo DJ. Platelet monitoring for PCI: which test is the one to choose? Hamostaseologie. 2009;29(4):376–80.
Article CAS PubMed Google Scholar
Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261–73. https://doi.org/10.1016/j.jacc.2013.07.101.
Article CAS PubMed Google Scholar
Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382(9892):614–23. https://doi.org/10.1016/s0140-6736(13)61170-8.
Aradi D, Gross L, Trenk D, et al. Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial. Eur Heart J. 2019;40(24):1942–51. https://doi.org/10.1093/eurheartj/ehz202.
Ignjatovic V, Pavlovic S, Miloradovic V, et al. Influence of different β-Blockers on platelet aggregation in patients with coronary artery disease on dual antiplatelet therapy. J Cardiovasc Pharmacol Ther. 2016;21(1):44–52. https://doi.org/10.1177/1074248415581175.
Article CAS PubMed Google Scholar
Janssen PWA, Bergmeijer TO, Vos GA, et al. Tailored P2Y(12) inhibitor treatment in patients undergoing non-urgent PCI-the popular risk score study. Eur J Clin Pharmacol. 2019;75(9):1201–10. https://doi.org/10.1007/s00228-019-02696-z.
Angiolillo DJ, Capodanno D, Danchin N, et al. Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score. JACC Cardiovasc Interv. 2020;13(5):606–17. https://doi.org/10.1016/j.jcin.2020.01.226.
Hernandez-Suarez DF, Melin K, Marin-Maldonado F, et al. Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial. BMJ Open. 2020;10(8):e038936. https://doi.org/10.1136/bmjopen-2020-038936.
Article PubMed PubMed Central Google Scholar
Hasan MS, Basri HB, Hin LP, et al. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. Int J Neurosci. 2013;123(3):143–54. https://doi.org/10.3109/00207454.2012.744308.
Article CAS PubMed Google Scholar
Jiang XL, Samant S, Lesko LJ, et al. Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015;54(2):147–66. https://doi.org/10.1007/s40262-014-0230-6.
Article CAS PubMed PubMed Central Google Scholar
Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12(16):1521–37. https://doi.org/10.1016/j.jcin.2019.03.034.
Zawbaa HM, El-Gendy A, Saeed H, et al. A study of the possible factors affecting COVID-19 spread, severity and mortality and the effect of social distancing on these factors: Machine learning forecasting model. Int J Clin Pract. 2021;75(6):e14116. https://doi.org/10.1111/ijcp.14116.
Article CAS PubMed Google Scholar
Sridharan K, Ramanathan M, Al BR. Evaluation of supervised machine learning algorithms in predicting the poor anticoagulation control and stable weekly doses of warfarin. Int J Clin Pharm. 2023;45(1):79–87. https://doi.org/10.1007/s11096-022-01471-y.
Article CAS PubMed Google Scholar
Al’Aref SJ, Maliakal G, Singh G, et al. Machine learning of clinical variables and coronary artery calcium scoring for the prediction of obstructive coronary artery disease on coronary computed tomography angiography: analysis from the CONFIRM registry. Eur Heart J. 2020;41(3):359–67. https://doi.org/10.1093/eurheartj/ehz565.
Article CAS PubMed Google Scholar
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77. https://doi.org/10.1093/eurheartj/ehx393.
Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49(6):657–66. https://doi.org/10.1016/j.jacc.2006.10.050.
Article CAS PubMed Google Scholar
Li Z, Dong W, Yang D, et al. Body weight, CYP2C19, and P2Y12 receptor polymorphisms relate to clopidogrel resistance in a cohort of Chinese ischemic stroke patients with aspirin intolerance. Eur J Clin Pharmacol. 2020;76(11):1517–27. https://doi.org/10.1007/s00228-020-02946-5.
Article CAS PubMed Google Scholar
Zheng P, Yu Z, Li L, et al. Predicting blood concentration of tacrolimus in patients with autoimmune diseases using machine learning techniques based on real-world evidence. Front Pharmacol. 2021;12:727245. https://doi.org/10.3389/fphar.2021.727245.
Article CAS PubMed PubMed Central Google Scholar
Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015;36(27):1762–71. https://doi.org/10.1093/eurheartj/ehv104.
Article CAS PubMed Google Scholar
Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y(12) receptor-inhibiting therapies. Circulation. 2017;136(20):1955–75. https://doi.org/10.1161/circulationaha.117.031164.
Article CAS PubMed Google Scholar
Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011;124(10):1132–7. https://doi.org/10.1161/circulationaha.111.029165.
Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–75. https://doi.org/10.1056/NEJMoa0808227.
Article CAS PubMed Google Scholar
Puymirat E, Simon T, Cayla G, et al. Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 Years in the FAST-MI program (French Registry of Acute ST-elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015. Circulation. 2017;136(20):1908–19. https://doi.org/10.1161/circulationaha.117.030798.
Saito Y, Nishi T, Wakabayashi S, et al. Validation of the ABCD-GENE score to identify high platelet reactivity in east Asian patients undergoing percutaneous coronary intervention. Int J Cardiol. 2021;327:15–8. https://doi.org/10.1016/j.ijcard.2020.11.022.
Miura G, Ariyoshi N, Sato Y, et al. Genetic and non-genetic factors responsible for antiplatelet effects of clopidogrel in Japanese patients undergoing coronary stent implantation: an algorithm to predict on-clopidogrel platelet reactivity. Thromb Res. 2014;134(4):877–83. https://doi.org/10.1016/j.thromres.2014.07.018.
Comments (0)